U.S. biotech firms are queuing up to list in South Korea, tempted by the promise of strong valuations amid a welcoming base of investors.
At least four such companies are seeking listings in the Asian country, according to NH Investment & Securities Co. and Eugene Investment & Securities Co. That’s a significant number given that there are currently only 20 overseas firms listed in South Korea, according to data compiled by Bloomberg.
